A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Clinical trial NCT04868708 · COMPLETED
Trial details
- NCT number
- NCT04868708
- Sponsor
- Akeso
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-01
- Primary completion
- 2024-02-28
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.